Humira adalimumab: Phase III started

Abbott began the double-blind, placebo-controlled, international Phase III M11-313 and M11-810 trials to evaluate subcutaneous Humira given weekly or every other week for up to 36 weeks in a total of about 600 patients with moderate to severe hidradenitis suppurativa. The chronic, inflammatory skin disease is characterized by painful, recurrent abscesses and nodules. ...